Stocks › ZBH
Zimmer Biomet Holdings, Inc. (ZBH) stock analysis
WEAK BUY 17% confidence · analysed Oct 13, 2026
On Oct 13, 2026, our model rated Zimmer Biomet Holdings, Inc. (ZBH) WEAK BUY with 17% confidence at a price of $92.17. That means the signals lean positive, but they are mixed, so conviction is low.
Technical picture
The 14-day RSI is 46, close to the neutral 50 line, so momentum is balanced.
MACD is above its signal line, a sign that short-term momentum is turning up.
The price has slipped below its 50-day moving average but is still above the 200-day: a pullback inside a longer-term uptrend.
Volume is about normal (0.8x the 20-day average).
Trend structure and money flow
Market structure: ranging / no clear structure.
The most recent swing high is $100.68 and the swing low is $78.70; traders often treat these as resistance and support.
Price is sitting in a bearish order block, a zone where large sellers stepped in before, so upside may stall here.
Fundamentals
The PEG ratio is 0.56, which looks cheap relative to its expected growth.
The company reports a profit margin of 9.5% and revenue growth of +4.8%.
In its latest quarter it earned $2.07 per share, which beat the $2.01 analysts expected, with revenue +4.8% year over year.
Wall Street's average rating is 2.5 on a 1 (strong buy) to 5 (sell) scale, roughly a "buy", with an average price target of $106.82.
The next earnings report is expected around Nov 4, 2026; prices often move sharply around earnings.
Trade plan from the model
The model's long / bullish plan uses an entry near $91.64, a target of $94.49 (+3.1%) and a stop-loss at $87.14 (-4.9%).
That is a reward-to-risk ratio of about 0.6 to 1: the potential loss is bigger than the gain, a weak setup.
The plan has a time limit: reassess by Oct 23, 2026 whatever the price does.
The model's one-paragraph read
Leans BUY — composite score +0.17 (WEAK BUY). Technicals: RSI 46.05, MACD bullish, price below SMA50. Fundamentals: PEG 0.56, margin 9.5%, revenue growth 4.8%. Financial results: YoY revenue +4.8%, last EPS surprise +3.0%, next earnings 2026-11-04. Smart Money Concepts: ranging / no clear structure, price retesting a bearish order block. FinGPT news read: positive. Memory: 1 prior look(s); 100% of directional calls matched later price. Suggested levels: entry $91.64, target $94.49, stop-loss $87.14, exit by 2026-10-23 (10-calendar-day max hold (time-stop; reassess by this date regardless of P&L)).
Past ratings for ZBH
| Date | Verdict | Confidence | Price | Move since | |
|---|---|---|---|---|---|
| Oct 13, 2026 | WEAK BUY | 17% | $92.17 | — | |
| Oct 12, 2026 | SKIP | 1% | $89.14 | +3.4% |
"Move since" compares each call's price with the latest analysed price.
Other Healthcare stocks we cover
ALC · AMGN · AMRX · ANIP · ASTH · ATEC · ATRC · BCRX · BDX · BIIB · BMY · BSX
Frequently asked questions
Is ZBH a buy right now?
As of Oct 13, 2026, our automated model rates Zimmer Biomet Holdings, Inc. (ZBH) WEAK BUY with 17% confidence: the signals lean positive, but they are mixed, so conviction is low. This is a model output for education, not personal investment advice.
What is the price target for ZBH?
The model's most recent plan targets $94.49 with a stop-loss at $87.14, from an entry near $91.64.
When does Zimmer Biomet Holdings, Inc. report earnings next?
The next earnings report is expected around Nov 4, 2026.
What does a WEAK BUY rating mean?
A WEAK BUY rating means the signals lean positive, but they are mixed, so conviction is low.
For information and education only. Not investment advice. Ratings are produced by an automated model, can be wrong, and may be out of date. Do your own research; you can lose money investing. The site's author may hold positions in stocks discussed here.